Managing the microbiome raises new hope for autism treatment
The number of children born with autism spectrum disorder — a cause of lifelong developmental disorders — is growing, and there is no effective FDA-approved treatment. But research by Fulton Schools Professors Rosa Krajmalnik-Brown and James Adams is showing promise for progress toward a viable treatment. They have discovered that those with autism have abnormal microbial conditions, and that adjusting the microbiota using healthy bacteria can help ease the gastrointestinal and behavioral symptoms of the disease. Krajmalnik-Brown and Adams are leading research to advance microbial transfer therapy and microbiome transplants in efforts to manage the disease.